Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders].

Medicina clinica - 28 Oct 2006

Remacha Angel F, Puget Guiomar, Nomdedéu Josep F, Estivill Camino, Sardà M Pilar, Canals Carme

Abstract excerpt

BACKGROUND AND OBJECTIVE: Polycythemia vera (PV) and essential thrombocytemia (ET) are chronic myeloproliferative diseases (MPD) characterized by overactive hemopoiesis. A single point mutation of JAK2 (Val617Phe) has been detected in PV, ET and myelofibrosis (MF). The aim of this work was to investigate the JAK2 mutation in patients with MPD and to compare the results to those of the endogenous formation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA
Share to Erythroid Precursor Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Philadelphia Chromosome

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Thrombocytosis

Source

Identifiers

PMID: 17145024
DOI: 10.1157/13094416

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders].PMID 17145024Read ↗

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].Semantic proximity Read ↗

The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.Semantic proximity Read ↗

[Myeloproliferative diseases caused by JAK2 mutation].Semantic proximity Read ↗

A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.Semantic proximity Read ↗

Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms.Semantic proximity Read ↗

Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.Semantic proximity Read ↗

Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.Semantic proximity Read ↗

The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.Semantic proximity Read ↗

[Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].Semantic proximity Read ↗

In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele.Semantic proximity Read ↗

[Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].Semantic proximity Read ↗

[The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.